Welcome to the Elipse™ Program

The world’s first and only weight loss device that requires no surgery, endoscopy, or anesthesia*

• Placed during a brief 20-minute visit¹ and passes naturally after approximately 16 weeks²
• Patients lose an average of 10 to 15kg and 10 to 15% TBWL after approximately 16 weeks of Elipse therapy² to ¹¹
• 15,000 balloons distributed worldwide
• The program includes professional follow-up over 6-months along with a smart scale and app to track weight loss.**

*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. **The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program. Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.


TBWL: Total Body Weight Loss
We surveyed 9,800 overweight and obese patients around the world

Patients’ demands and expectations remain unmet with existing weight loss procedures

Vast 2018 Consumer Research across Europe, Middle East, China and U.S.A.

Screening a representative panel of 9,800 patients

Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018
An increasing number of patients lack satisfying treatment options

76% are not fully satisfied with previously tried weight loss solutions

78% are not fully satisfied with previously tried diet plans

1 in 3 people are overweight or obese in the US, EU5, China and the UAE*

1. Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018 Q3C. On a scale of 1 to 10, where 1 is not at all satisfied and 10 is extremely satisfied, how satisfied are you with the following? Think about your experience of the whole process.
Global level. Base: n=4831
Satisfied: 8-10/10, neither 4-7/10, unsatisfied 1-3/10

2. Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018 Q3C. On a scale of 1 to 10, where 1 is not at all satisfied and 10 is extremely satisfied, how satisfied are you with the following? Think about your experience of the whole process.
Global level. Base: n=4831
Satisfied: 8-10/10, neither 4-7/10, unsatisfied 1-3/10

*Based on WHO, Eurostat and US Census data
4.3% would consider the Elipse Balloon

Globally, 7.2% of eligible patients would consider treatment from an HCP to manage weight loss

Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018, Population, Age, and Income Data taken from Census.gov Funnels computed using cascading base methodology
Bothered by weight is determined at 4 – 7 on a 7 point scale Considerers needs to be assessed by medical practitioner to assess their eligibility to the treatment
*HCP = Health Care Professional

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population in considered areas</td>
<td>100%</td>
<td>547.6 million</td>
</tr>
<tr>
<td>Target ages (18-65) and target BMI (&gt;27)</td>
<td>33.6%</td>
<td>183.8 million</td>
</tr>
<tr>
<td>Target household income</td>
<td>26.8%</td>
<td>146.7 million</td>
</tr>
<tr>
<td>Bothered by their weight</td>
<td>19.7%</td>
<td>108.2 million</td>
</tr>
<tr>
<td>Ready to act in the next 2 years</td>
<td>13.1%</td>
<td>71.9 million</td>
</tr>
<tr>
<td>Would consider HCP intervention</td>
<td>7.2%</td>
<td>39.3 million</td>
</tr>
<tr>
<td>Would consider Elipse</td>
<td>4.3%</td>
<td>23.7 million</td>
</tr>
</tbody>
</table>

60% of those that would consider HCP* intervention, would consider Elipse
Elipse is an aesthetic lifestyle treatment for moderate to high BMI patients

14x more overweight and obese people consider weight loss treatments than facial wrinkle treatments

Weight loss is the natural step before body contouring procedures: CoolSculpting, Liposuction, Abdominoplasty, Belkyra*

Allurion consumer market research: 9,800 respondents; 8 geographies; Oct 2018 Q2B. Are you considering having any of the following facial or body treatments provided by a physician / healthcare professional in the next 2 years? Global level. Base: n=6394

*The safety and effectiveness of the non-Elipse treatments has not been evaluated by Allurion Technologies, Inc.
Aesthetics:
Introducing a New Holistic Approach to the Body

SLIM

Lose weight with Elipse (for overweight patients)¹

SCULPT

Remove stubborn fat with Liposuction or Cryolipolisis²

TONE

Rebuild muscle with high intensity focused electromagnetics³

LIFT

Tighten the skin with radiofrequency⁴


The safety and effectiveness of the non-Elipse treatments has not been evaluated by Allurion Technologies, Inc.
Gastric balloon procedures have a reduced uptake due to the lack of patient friendly solutions

Perceived reasons for NOT considering a weight loss balloon treatment requiring endoscopy and anesthesia

Q16. When considering the weight loss balloon treatment requiring an endoscopy and anesthesia, why are you not interested in this treatment?

Global data Base: Q16 n=2377, Q18A n=4341, Q18B n=4341

- 49% Risk of damage to throat/oesophagus
- 49% Don’t want anesthesia
- 38% Discomfort
- 29% Pain
- 15% Downtime / Recovery time

65% Fear of complications
3 times more patients would consider the Elipse Balloon than those who would consider bariatric surgery.

60% of those that would consider HCP* intervention, would consider Elipse.

19% of those that would consider HCP intervention, would consider bariatric surgery.

Q4A. Have you ever discussed your weight with a health care professional such as a [UK ONLY: GP] [US ONLY: PCP] / doctor, specialist, dietician or nutritionist?

Global data. Base: asked to all, n=8281
Endoscopy, anesthesia and surgery are major barriers to treatment for overweight and obese patients

40% would only be willing to try a treatment that doesn’t require any surgery or anesthesia

over 6x more patients would prefer intragastric balloons placed by swallowing versus endoscopic placement and removal by natural passage versus endoscopic*

Q18A. What is your preference for how a weight loss balloon is placed in your stomach? Q18B. What is your preference for how a weight loss balloon at the end of your treatment is removed from your stomach? Global data. Base: Q16 n=3028, Q18A n=6152, Q18B n=6152. Don’t know/ not sure were also included in the options to answer. *In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal.

Allurion consumer market research: 9,800 respondents; 8 geographies; Oct 2018 Q11. Which of the following weight loss treatment options would you be willing to try if it was proven to be an effective weight loss treatment? Global data. Base: n=3687. Likely to ask HCP for solution not tried.
Drivers

Non-surgical treatment is a key preference factor for those considering weight loss treatment

IMPORTANT FACTORS IN HCP INTERVENTION TREATMENT
Top 6 most important

- Gives me the results I want
- Provides results I can see
- Quick results
- Recommended by my doctor/provider
- No anesthesia is required
- Non surgical treatment

Q10. What would you be looking for from a physician/health care provider administered weight loss treatment?
Global data. Base: n=2461. Likely to ask HCP for solution not tried.
The Elipse Balloon is the world’s first and only weight loss device requiring no surgery, endoscopy, or anesthesia*

*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal

01 Balloon film

- Much thinner than silicone balloons¹
- Flexible enough to fold into a capsule and safely pass through the GI tract²,³,⁴
- Durable enough to spend months in the stomach²,³,⁴

¹Internal Allurion lab notebook data
²Clinical Reports: DAA018, DAA069 and DAA105
The Elipse Balloon is the world’s first and only weight loss device requiring no surgery, endoscopy, or anesthesia*

![Illustration](image_url)

*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal

**Swallowing**

- The balloon is rolled into the capsule and swallowed along with a thin Delivery Catheter to facilitate filling
- In a recent clinical study¹ 99.9% of patients (n 1623) were able to swallow the device with only 32% needing stylet assistance

¹ Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain
The Elipse Balloon is the world’s first and only weight loss device requiring no surgery, endoscopy, or anesthesia*

*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal

Fill valve
- Made from thin film
- Seals shut after the Delivery Catheter is pulled out
The Elipse Balloon is the world’s first and only weight loss device requiring no surgery, endoscopy, or anesthesia*

*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal

04
Release valve

- Made from a thin film and a degradable filament
- Only exposed to the inside of the device to allow for controlled opening
- Weakens over time, then opens at pre-determined time allowing the balloon to empty

1. Clinical Reports: DAA018, DAA069 and DAA105
An improved patient experience
from start to finish

01
The Elipse Balloon is swallowed in a physician’s office

02
The Elipse Balloon is filled with 550ml of liquid in the stomach

03
At approximately 16 weeks after placement, the Elipse Balloon self-empties and passes naturally¹

¹In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal

Two X-rays of the patient will confirm
1) that the capsule is in the right position
2) a second X-ray to confirm the balloon is filled.

Patients want to get results and achieve lifestyle changes without surgery, endoscopy or anesthesia

IMPORTANT FACTORS FOR HCP TREATMENT ACCORDING TO MARKET RESEARCH

<table>
<thead>
<tr>
<th>Factor</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non surgical treatment</td>
<td>28%</td>
</tr>
<tr>
<td>No surgery or anesthesia is required</td>
<td>25%</td>
</tr>
<tr>
<td>Recommended by my doctor/provider</td>
<td>24%</td>
</tr>
<tr>
<td>Quick results</td>
<td>21%</td>
</tr>
<tr>
<td>Provides results I can see</td>
<td>21%</td>
</tr>
<tr>
<td>Gives me the results I want</td>
<td>20%</td>
</tr>
<tr>
<td>Makes me feel good about myself</td>
<td>20%</td>
</tr>
<tr>
<td>Long term lifestyle changes</td>
<td>20%</td>
</tr>
</tbody>
</table>

Q10. What would you be looking for from a physician/health care provider administered weight loss treatment? Global data. Base: n=2461

Q19A. What do you like about the Elipse Balloon? Global data. Base: n=2538
The first and only game-changing device that matches patients’ needs and expectations

01  
A swift experience

The Elipse Balloon is swallowed during a brief 20 minute visit1 and passes naturally after approximately 16 weeks2*

Your patient enjoys the privacy of an outpatient treatment: no one in his or her circle needs to know they had the placement

02  
Effective results

After approximately 16 weeks of Elipse therapy, patients lose an average of 10 to 15kg and 10 to 15% TBWL2 to11.

03  
Multidisciplinary support

Patients receive medical and nutritional support for the entire duration of the program along with a smartphone app and a connected scale**

---

1. In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal

8. Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA
9. Genco et al. Submitted to SOARD. Abstract A185, presented at Obesity Week, 2018, Nashville, USA
10. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain

**The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program. Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.

TBWL: Total Body Weight Loss
Efficacy and safety of the Elipse Balloon has been demonstrated in multiple clinical studies

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Year Published</th>
<th>n</th>
<th>Mean Starting BMI (kg/m²)</th>
<th>Weight Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU Multi-Center Study¹</td>
<td>2017</td>
<td>34</td>
<td>34.8 (27.0-40.0)</td>
<td>10% TBL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.9 ↓BMI</td>
</tr>
<tr>
<td>Greek Experience²</td>
<td>2017</td>
<td>12</td>
<td>36.1</td>
<td>14.6% TBL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.4 ↓BMI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15.4kg/34lbs</td>
</tr>
<tr>
<td>Italian Experience³</td>
<td>2017</td>
<td>38</td>
<td>38.6</td>
<td>11.6% TBL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.2 ↓BMI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12.7kg/28lbs</td>
</tr>
<tr>
<td>Faisal Clinic Experience⁴</td>
<td>2017</td>
<td>51</td>
<td>32.1 (27.3-39.7)</td>
<td>10.4% TBL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40.8% EWL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.4 ↓BMI</td>
</tr>
<tr>
<td>Kuwait Multicenter Study⁵</td>
<td>2017</td>
<td>135</td>
<td>32.1 (27.3-39.7)</td>
<td>15.1% TBL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.9 ↓BMI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13kg/28.6lbs</td>
</tr>
</tbody>
</table>

Efficacy and safety of the Elipse Balloon has been demonstrated in multiple clinical studies

<table>
<thead>
<tr>
<th>Study Description</th>
<th>Year Published</th>
<th>n</th>
<th>Mean Starting BMI (kg/m²)</th>
<th>Weight Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expanding the Reach of Intragastric Balloons: First Multicenter Results of Elipse Balloon in Non-Core User Groups¹</td>
<td>2019 (Submitted for publication)</td>
<td>64</td>
<td>35±4.6</td>
<td>After 4 months, at the time of excretion 16 % TBL 5.7 ↓ BMI</td>
</tr>
<tr>
<td>Italy Metabolic Multicenter Study²</td>
<td>2019 (Submitted for publication)</td>
<td>324</td>
<td>36.8</td>
<td>13.75% TBL 4.98 ↓ BMI 14.3 Kg</td>
</tr>
<tr>
<td>Kuwait 1 Year Post-Excretion Follow-up³</td>
<td>2019</td>
<td>112</td>
<td>34.3</td>
<td>10.9% TBL at 6 months 7.9% TBL at 1 year post device excretion</td>
</tr>
<tr>
<td>Multi-Center Experience in 1623 Consecutive Patients⁴</td>
<td>2019 (Submitted for publication)</td>
<td>1623</td>
<td>34.2±5.4</td>
<td>After 4 months, 13.6±5.7% TBL 4.9 ↓ BMI 99.9% of patients were able to swallow the device</td>
</tr>
<tr>
<td>An Intensive 16-week Nutritional, Exercise and Behavior Modification Program: Comparison With or Without the Elipse Intragastric Balloon⁵</td>
<td>2019</td>
<td>471</td>
<td>Elipse plus LI 36.7±5.7</td>
<td>After 4 months, 14.1±5.2 (Elipse + LI) vs. 6.7±4.6 (LI Alone) %TBWL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LI alone 36.8±5.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LI = lifestyle intervention</td>
<td></td>
</tr>
</tbody>
</table>

1. Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA
2. Genco et al. Submitted to SOARD. Abstract A185, presented at Obesity Week, 2018, Nashville, USA
4. Raftopoulos et al. Abstract 237, presented at IFSO 2019, Madrid, Spain
Excellent safety profile with proven efficacy

Largest Elipse Data Collection to Date\(^1\)
1623 consecutive patients, in 19 centers, across 7 countries

4 months

TBWL was
13.6±5.7%  
Mean Weight Loss
12.9±6.5 kg  
BMI reduction
4.9±3.3 kg/m\(^2\)

99.9% of patients were able to swallow the device

All metabolic parameters improved (measured in a subset of 406 patients)

\(^1\) Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain
Lifestyle modification

When coupled with a 16-week intensive lifestyle modification, Elipse leads to significant weight loss vs. lifestyle modification alone1*.

PERCENTAGE OF PATIENTS ACHIEVING 10% TBWL AT 16 WEEKS

Intensive lifestyle modification included a structured curriculum-based nutritional, exercise and behavior modification program.

*The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program.
Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.
A temporary balloon does not mean temporary weight loss

Lose Weight and Keep It Off

72% of average weight loss was sustained at 12 month follow up

One clinical study with 95 patients has shown that 72% of average weight loss with Elipse can be sustained at 12 month follow up.

Weight Loss with Gastric Balloons

Please note these are results from Orbera Gastric Balloon

**WEIGHT LOSS CURVE AFTER ORBERA IGB PLACEMENT**

80% of weight loss of a 6-month Orbera balloon occurs in the first three months

---

Elipse Safety Profile

Allurion Internal Vigilance Data

≈ 98%

No reported adverse events

In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. Some individuals may not be eligible to receive the Elipse Balloon. Doctors take a detailed medical history and perform a physical examination to determine patients’ eligibility.

The Elipse Balloon is a temporary weight loss aid for adults over the age of 18 who are overweight or obese, defined as a body mass index (BMI) ≥ 27. The Elipse Balloon can only be administered by a healthcare professional who is knowledgeable about the use of the Elipse Balloon.

The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program. Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.

ADVERSE EVENTS RATES (%)
MARCH 2016 – JUNE 2019

Total units distributed = 15,200

Total adverse events reported were less than 2% of total Elipse Balloons placed

The 10 Most Relevant Types
Premature Deflation 0.43%
Intolerance 0.25%
Small Bowel Obstruction 0.11%
Hyperinflation 0.05%
Dysphagia 0.05%
Gastric Outlet Obstruction 0.03%
Gastric Perforation 0.02%
Incomplete Device Emptying 0.02%
Pancreatitis 0.01%
Gastroparesis 0.01%

In rare cases, the empty balloon may be vomited instead of passing through the GI tract. Although startling to the patient, vomiting of the balloon has not been associated with any reported adverse events to date.
Common side effects are pain, nausea and GERD

Please note that this is the safety profile of Orbera Gastric Balloon

META-ANALYSIS OF 80 ORBERA IGB STUDIES INCLUDING 8,506 PATIENTS

<table>
<thead>
<tr>
<th>Side Effect</th>
<th>Rate %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>33.7</td>
</tr>
<tr>
<td>Nausea</td>
<td>29</td>
</tr>
<tr>
<td>GERD</td>
<td>18.5</td>
</tr>
<tr>
<td>Gastric erosions/ulcers</td>
<td>12/2</td>
</tr>
<tr>
<td>Migration</td>
<td>1.4</td>
</tr>
<tr>
<td>Small bowel obstruction</td>
<td>0.3</td>
</tr>
<tr>
<td>Perforation</td>
<td>0.1</td>
</tr>
<tr>
<td>Death</td>
<td>0.08</td>
</tr>
</tbody>
</table>

- Early removal: 7.5%
- Serious side effects are not common

Weight loss with Elipse therapy may improve patient comorbidities\textsuperscript{1,2}

Treatment produced a reduction in the factors related to clinical diagnosis of metabolic syndrome such as:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Waist Circumference, (↓8.4-12.5 cm)</td>
</tr>
<tr>
<td>02</td>
<td>Triglycerides (↓16.4-34 mg/dl)</td>
</tr>
<tr>
<td>03</td>
<td>Systolic Blood Pressure (↓7-9.6 mmHg)</td>
</tr>
<tr>
<td>04</td>
<td>Diastolic Blood Pressure (↓5-5.8 mmHg)</td>
</tr>
</tbody>
</table>

\textsuperscript{1} Machytka et al Endoscopy. 2017 Feb;49(2):154-160.
Elipse therapy may improve patient quality of life\textsuperscript{1}

Elipse therapy improved the mean QOL across all domains* 

CHANG E IN IWQOL SCORE FROM BASELINE TO TRIAL EXIT


*A small percentage of patients don't respond to the treatment.
## PHYSICIAN GROSS PROFIT

<table>
<thead>
<tr>
<th>Monthly productivity</th>
<th>5 balloons</th>
<th>10 balloons</th>
<th>17 balloons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monthly practice revenue</td>
<td>$25 k</td>
<td>$50 k</td>
<td>$85 k</td>
</tr>
<tr>
<td>Monthly gross profit</td>
<td>$13 k</td>
<td>$26 k</td>
<td>$44 k</td>
</tr>
<tr>
<td>Annual practice revenue</td>
<td>$300 k</td>
<td>$600 k</td>
<td>$1,020 k</td>
</tr>
<tr>
<td>Annual gross profit</td>
<td>$154 k</td>
<td>$308 k</td>
<td>$523 k</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time allocation (days a month)</th>
<th>&gt; 1 day/m</th>
<th>&gt; 2 days/m</th>
<th>&gt; 3 days/m</th>
</tr>
</thead>
</table>

### Time spent by treatment

<table>
<thead>
<tr>
<th>Time spent by treatment</th>
<th>60 min</th>
</tr>
</thead>
</table>

### Physician gross profit per hour*

<table>
<thead>
<tr>
<th>Physician gross profit per hour*</th>
<th>$2563/h</th>
</tr>
</thead>
</table>

---

*Gross profit per treatment divided by physician time spent per treatment: consultation: 1x30 min, placement: 20 min, follow-up: 1x10 min

---

**Gross profit per treatment divided by physician time spent per treatment: consultation: 1x30 min, placement: 20 min, follow-up: 1x10 min**

---

**Highly attractive practice economics. Business case for 3 levels of account productivity.**

**$5000 program price**

<table>
<thead>
<tr>
<th>Price of the balloon</th>
<th>$1 722</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dietician fees</td>
<td>$400</td>
</tr>
<tr>
<td>Psychologist/coach fees</td>
<td>$115</td>
</tr>
<tr>
<td>Out of pocket expenses (XRAY)</td>
<td>$200</td>
</tr>
</tbody>
</table>

**HCP fees**

<table>
<thead>
<tr>
<th>HCP fees</th>
<th>$2563</th>
</tr>
</thead>
</table>

---

**© 2019 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL**

---

28
Dedicated support to develop Elipse activities

Get support from day 1
- Place your first 10 balloons with the support of the Allurion team
- Leverage in-clinic marketing tools
- Get support in creating your multidisciplinary Elipse Program

Benefit from Allurion expertise
- Clinical expertise
- Market research
- Allurion Academy
- Staff training
- Online advertising
- Marketing rewards
- Customer Care Manager

Increase patient engagement and follow-up quality
- Long-term program
- Connected smart scale
- Allurion app
Testimonials
Inspire others: share your patient success stories

“Before, I was so big that I had a lot of difficulties with mobility and there were days when I wouldn’t be able to leave the house. Now, I feel like I have my life back again.”

Michael, 67, UK, in the Daily Mail

“I swallowed the capsule without too much difficulty — I felt a bit queasy but nothing more (...) I’ve lost 25 inches all over and I can fit into a size 16 comfortably.”

Kayleigh, 28, UK, in the Daily Mail – Spire Thames Valley Dr Humadi

“It was fantastic (...) I’ve lost 16 pounds in 4 weeks, my energy and my confidence are back, I’m fitting into clothes I haven’t worn for 30 years!”

Hetsie, 42, UK, on Channel 4

“I was going straight to obesity (...) I finished the treatment 6 months ago but I still feel full faster than before. (...) I lost 20 kilos thanks to the Elipse Balloon.”

Véronique, 50, France, in Femme Actuelle

Actual Elipse Patient
*Results may vary from one participant to another. A small percentage of patients don’t respond to the treatment.*
Our purpose

To help people achieve their full potential with innovative, scalable, and trusted experiences

Veronique, 50
Lost 20kg
No longer afraid to be in family photos

Claire, 42
Lost 10kg
Can run after her son without losing her breath
Our purpose
A message from our founders

01 Ethics first
02 Openness and transparency
03 Scientific validation
04 Data-driven decision making
05 Employee Fulfillment
100% growth per year:
join the Allurion success story

2009
Allurion is founded by two Harvard Medical School students, supported by a world class scientific advisory board

2017
Allurion raises an additional 26.5 million USD

2019
Commercial in 21 countries in Europe, the Middle East and S. America
15,000 balloons distributed worldwide